

ORIGINAL ARTICLE

Open Access



High repetitive arginine in the anterior of PCV3 capsid protein is a severe obstacle for its expression in *E. coli*

Bing Yan Liu, Bin Gao, Meng Zhi Liu, Ting Ting Zhang, Bao Shan Liu* and Ze Liang Chen*

Abstract

Porcine circovirus type 3 (PCV3) is a novel circovirus identified in sows with PDNS-like clinical signs and reproductive failure. The capsid protein (CAP) of PCV3 is expected to be an effective vaccine candidate. Here, we expressed the original capsid protein, truncated capsid protein without anterior highly repetitive arginine (Δ CAP) and their codon-optimized counterparts in *E. coli*. These results showed that lots of repeated arginine could severely lower the expression of PCV3 capsid protein in *E. coli*. At the same time, the recombinated truncated PCV3 capsid protein forms typical virions. The efficient expression of capsid protein is expected to serve the development of PCV3 vaccines and other studies of PCV3 capsid protein.

Keywords: PCV3, Capsid protein, Expression, High repetitive, Arginine, Obstacle

Key points

1. High repetitive arginine in the anterior of PCV3 CAP severely hinders its expression in *E. coli*.
2. The purified recombinated Δ CAP automatically assemble into typical virions.
3. The efficient expression of CAP serves studies of PCV3.

Introduction

Circoviruses are a class of the smallest DNA viruses, with a particle size of about 20 nm. Porcine circoviruses include Porcine circovirus 1 (PCV1), PCV2: Porcine circovirus 2 (PCV2), and Porcine circovirus 3 (PCV3). PCV3 is a novel circovirus identified in 2017 in sows with reproductive failure and clinical signs like pig dermatitis and nephrotic syndrome (PDNS) (Palinski et al. 2017).

The capsid and replicase proteins of PCV3 are only 37% and 55% identical to PCV2 and bat circoviruses, respectively (Palinski et al. 2017). After the first confirmed case in the USA in 2017, PCV3 was subsequently identified in pigs in other countries such as China (Zhai et al. 2017), Italy (Faccini et al. 2017), Poland (Stadejek et al. 2017), Korea (Kwon et al. 2017), Russia (Yuzhakov et al. 2018), Japan (Hayashi et al. 2018), Brazil (Tochetto et al. 2018) Denmark Spain (Franzo et al. 2018) and Sweden (Ye et al. 2018). PCV3 DNA was even detected in the dog (4 of 44 dogs) (Zhang et al. 2018). It is also found that the PCV3 infection increased rapidly from late 2013 to early 2014 (Li et al. 2018). The high occurrence of PCV3 may pose a potential threat to the swine industry worldwide (Li et al. 2018). However, the processes resulting in the emergence and spread of PCV3 remain poorly understood (Li et al. 2018). Until today PCV3 has not been successfully cultured in vitro (Deng et al. 2018), which makes it difficult to study its pathogenesis, protein function, and vaccine.

To further study the structure and function of the virus and to develop a vaccine, the viral coat protein needs to be expressed. Prokaryotic expression in *E. coli* is the most mature and efficient expression method. However, in our previous study, the PCV3 capsid protein was barely

*Correspondence: lbslgy@syau.edu.cn; zeliangchen@yahoo.com
Key Laboratory of Livestock Infectious Diseases in Northeast China, Ministry of Education, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, No. 120, Dongling Road, Shenyang 110866, Liaoning, People's Republic of China

expressed in *E. coli*. So to understand the influence factor for the expression of the PCV3 capsid protein, the expression of PCV3 capsid protein in *E. coli* was tested after codon optimization and truncation.

Methods

Analysis of the sequence of the capsid protein

For high levels of expression in *E. coli*, the codon usage of the gene sequence of the capsid protein of PCV3 isolate (MK000387) was analyzed at the online *E. coli* Codon Usage Analysis 2.0 (<http://faculty.ucr.edu/~mmaduro/codonusage/usage.htm>). Then antigenic epitopes of the PCV3 capsid protein (CAP) were analyzed by the online program Bepipred Linear Epitope Prediction 2.0 and ElliPro at the website immune Epitope database and analysis resource (IEDB) (<http://www.iedb.org/>). Based on the analysis of the sequence, the intact PCV3 CAP and a truncated Capsid protein without anterior 32 amino acids (Δ CAP) were selected to express. At the same time, both amino acid sequences were codon-optimized for expression in *E. coli* utilizing the online Reverse Translate program of the Sequence Manipulation Suite (<http://www.bioinformatics.org/sms2>).

Construction of expression vector of the capsid protein

The codon optimization sequences of CAP and Δ CAP were synthesized and inserted into *Bam*H I and *Xho* I site of a pET-28a plasmid vector respectively to construct the recombinant plasmid pET-3CAP-O and pET- Δ 3CAP-O by Sangon Biotech (Shanghai) Co., Ltd.

Using DNA samples identified as PCV3 positive by PCR (Palinski et al. 2017) as templates, the gene sequences of CAP and Δ CAP were amplified by Polymerase chain reaction (PCR) with two pairs of primer (Table 1). After digested by the restriction enzyme *Bam*H I and *Xho* I, they were cloned into pET-28a plasmid vector respectively to construct the recombinant plasmid pET-3CAP and pET- Δ 3CAP. The recombinant plasmid was introduced into *E. coli* BL21 (DE3) cells by transformation using traditional chemical transformation methods.

Table 1 The primers for the sequences of CAP and Δ CAP

Probe/primer	The DNA sequence (5'-3')	Tm	Amplicon size (bp)
CAPF	tttt ggatcc ATGAGACAGAGCTATA TTCAG	55.40	650
Δ CAPF	tttt ggatcc CCCACAGCTGGCACATAC	58.09	554
CAPR	tttt ctcgag TTCACTTAGAGAACG GACTTG	55.31	

The lowercase letters are protective bases and restriction sites, respectively

The recombinant bacteria with the plasmid pET-28a, pET-3CAP, pET- Δ 3CAP, pET-3CAP-O and pET- Δ 3CAP-O were cultured respectively in 5 mL ZYP-5052 medium in 37 °C until the OD₆₀₀ of the cultures reached 0.6. Then they were transferred to 20 °C for 12 h to induce the expression of the recombinant protein (Studier 2005).

Expression of the recombinant capsid and truncated capsid protein

The expressed cells were harvested by centrifugation and mixed with sodium dodecyl sulfonate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer containing β -mercaptoethanol for the SDS-PAGE, then loaded on 12% SDS-PAGE after heating the samples for 10 min at 100 °C. The polyacrylamide gel was stained using Coomassie Blue for visualizing the protein. The result was taken a photo (Fig. 1a) on a Tanon GIS system (Tanon, China), and protein expression was analyzed quantitatively by the ImageJ software (NIH, USA) basing on the proportion of their grey value in the total grey value.

The recombinant proteins resolved on SDS-PAGE gels were also transferred to the nitrocellulose membrane (Whatman, Germany) using the Mini Trans-Blot Transfer Unit (BIO-RAD, USA) for one hour. The membrane was blocked with 1% bull serum albumin (BSA) for 1 h at room temperature and incubated at room temperature for half an hour with anti-his tag monoclonal antibody (Sangon Biotech Co., Ltd., Shanghai, China) (1:5000) in 1% BSA. After being washed with PBST (50 mM potassium phosphate, 150 mM NaCl, 0.05% Tween 20, pH 7.2) for three times at 5 min interval, the membrane was incubated with a 1:2000 horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG for 0.5 h at room temperature. After further washing, the signal was detected using the colourimetric substrate DAB/H₂O₂ in the dark place for 15 min.

Purification and identification of the recombinant PCV3 capsid protein

Wet induced cells of the recombinant *E. coli* expressing Δ CAP were harvested by centrifugation at 5000×g for 10 min. The bacterial pellet was washed and resuspended in binding buffer (20 mM sodium phosphate, 500 mM NaCl, 20–40 mM imidazole, pH 7.4). Cell paste was lysed over 15 passages through the cell disrupter JN-Minipro (JUNENG NANO&BIO TECH.CO., LTD, Guangzhou, China) at 1000 bar pressure. Cell-lysate was clarified by centrifuging at 12,000×g for 10 min to remove the cell debris. Then the supernatant was loaded to a HisTrap FF column (GE, USA), which was connected to an AKTA prime chromatography system (GE Healthcare, Chalfont St. Giles, United Kingdom). After washing with 10

Original gene	1	ATG AGA CAC AGA GCT ATA TTC AGA AGA AGA CCC CGC CCA AGG AGA CGA CGA CGC CAC AGA
Codon-optimized	1	ATG CGC CAT CGC GCG ATT TTT CGC CGC CGC CCG CGC CCG CGC CGC CGC CGC CAT CGC
Amino acid	1	MET Arg His Arg Ala Ile Phe Arg Arg Arg Pro Arg Pro Arg Arg Arg Arg Arg His Arg
Original gene	61	AGG CGC TAT GTC AGA AGA AAA CTA TTC ATT AGG AGG CCC ACA GCT GGC ACA TAC TAC ACA
Codon-optimized	61	CGC CGC TAT GTG CGC CGC AAA CTG TTT ATT CGC CGC CCG ACC GCG GGC ACC TAT TAT ACC
Amino acid	21	Arg Arg Tyr Val Arg Arg Lys Leu Phe Ile Arg Arg Pro Thr Ala Gly Thr Tyr Tyr Thr
Original gene	121	AAG AAA TAC TCC ACC ATG AAC GTC ATT TCC GTT GGA ACC CCT CAG AAT AAT AAG CCC TGG
Codon-optimized	121	AAA AAA TAT AGC ACC ATG AAC GTG ATT AGC GTG GGC ACC CCG CAG AAC AAC AAA CCG TGG
Amino acid	41	Lys Lys Tyr Ser Thr MET Asn Val Ile Ser Val Gly Thr Pro Gln Asn Asn Lys Pro Trp
Original gene	181	CAC GCC AAC CAC TTC ATT ACC CGC CTA AAC GAA TGG GAA ACT GCA ATT AGC TTT GAA TAT
Codon-optimized	181	CAT GCG AAC CAT TTT ATT ACC CGC CTG AAC GAA TGG GAA ACC GCG ATT AGC TTT GAA TAT
Amino acid	61	His Ala Asn His Phe Ile Thr Arg Leu Asn Glu Trp Glu Thr Ala Ile Ser Phe Glu Tyr
Original gene	241	TAT AAG ATA CTA AAG ATG AAA GTT ACA CTC AGC CCT GTA ATT TCT CCA GCT CAG CAA ACA
Codon-optimized	241	TAT AAA ATT CTG AAA ATG AAA GTG ACC CTG AGC CCG GTG ATT AGC CCG GCG CAG CAG ACC
Amino acid	81	Tyr Lys Ile Leu Lys MET Lys Val Thr Leu Ser Pro Val Ile Ser Pro Ala Gln Gln Thr
Original gene	301	AAA ACT ATG TTC GGG CAC ACA GCC ATA GAT CTA GAC GGC GCC TGG ACC ACA AAC ACT TGG
Codon-optimized	301	AAA ACC ATG TTT GGC CAT ACC GCG ATT GAT CTG GAT GGC GCG TGG ACC ACC AAC ACC TGG
Amino acid	101	Lys Thr MET Phe Gly His Thr Ala Ile Asp Leu Asp Gly Ala Trp Thr Thr Asn Thr Trp
Original gene	361	CTC CAA GAC GAC CCT TAT GCG GAA AGT TCC ACT CGT AAA GTT ATG ACT TCT AAA AAA AAA
Codon-optimized	361	CTG CAG GAT GAT CCG TAT GCG GAA AGC AGC ACC CGC AAA GTG ATG ACC AGC AAA AAA AAA
Amino acid	121	Leu Gln Asp Asp Pro Tyr Ala Glu Ser Ser Thr Arg Lys Val MET Thr Ser Lys Lys Lys
Original gene	421	CAC AGC CGT TAC TTC ACC CCC AAA CCA ATT CTG GCG GGA ACT ACC AGC GCT CAC CCA GGA
Codon-optimized	421	CAT AGC CGC TAT TTT ACC CCG AAA CCG ATT CTG GCG GGC ACC ACC AGC GCG CAT CCG GGC
Amino acid	141	His Ser Arg Tyr Phe Thr Pro Lys Pro Ile Leu Ala Gly Thr Thr Ser Ala His Pro Gly
Original gene	481	CAA AGC CTC TTC TTT TTC TCC AGG CCC ACC CCA TGG CTC AAC ACA TAT GAC CCC ACC GTT
Codon-optimized	481	CAG AGC CTG TTT TTT TTT AGC CGC CCG ACC CCG TGG CTG AAC ACC TAT GAT CCG ACC GTG
Amino acid	161	Gln Ser Leu Phe Phe Phe Ser Arg Pro Thr Pro Trp Leu Asn Thr Tyr Asp Pro Thr Val
Original gene	541	CAA TGG GGA GCA CTG CTT TGG AGC ATT TAT GTC CCG GAA AAA ACT GGA ATG ACA GAC TTC
Codon-optimized	541	CAG TGG GGC GCG CTG CTG TGG AGC ATT TAT GTG CCG GAA AAA ACC GGC ATG ACC GAT TTT
Amino acid	181	Gln Trp Gly Ala Leu Leu Trp Ser Ile Tyr Val Pro Glu Lys Thr Gly MET Thr Asp Phe
Original gene	601	TAC GGC ACC AAA GAA GTT TGG ATT CGT TAC AAG TCC GTT CTC TAA
Codon-optimized	601	TAT GGC ACC AAA GAA GTG TGG ATT CGC TAT AAA AGC GTG CTG TAA
Amino acid	201	Tyr Gly Thr Lys Glu Val Trp Ile Arg Tyr Lys Ser Val Leu ***

Fig. 1 Expression and identification of recombinant PCV3 capsid proteins expressed in *E. coli*. **a** The SDS-PAGE analysis of the recombinant capsid protein of PCV3. M, protein marker; 1, control bacteria with pET-28a; 2, the bacteria with pET-3CAP; 3, the bacteria with pET-Δ3CAP; 4, the bacteria with pET-3CAP-O; 5, the bacteria with pET-Δ3CAP-O. **b** Western blots analysis of the expressed recombinant proteins using the anti-His antibody. The blot corresponds to lanes 1–5 from (a). The arrows represent the location of the recombinant ΔCAP (25 kDa), respectively. The expression of the recombinant CAP protein did not be detected

column volumes of binding buffer, the ΔCAP protein was eluted with the binding buffer containing 50, 100, 300 mM imidazole, pH 7.2. The collected fractions were identified by SDS-PAGE gels and Western-blot assay with positive serum of PCV3 and HRP-conjugated goat anti-pig IgG (No.D111051, Sangon Biotech Co., Ltd., Shanghai, China).

Transmission electron microscopy (TEM)

Two μg of purified ΔCAP were adsorbed onto a carbon-coated copper grid and incubated for about 1 min. Then, grids were dried using filter paper, negatively stained with 2% of phosphotungstic acid (PTA) for about 40 s, and viewed using an HT7700 transmission electron microscope (Hitachi, Japan), operating at 120 kV.

Results

Analysis of the sequence of the capsid protein


The analysis of the codon usage of the sequence of PCV3 capsid protein showed that 23% (51/214) of the PCV3 codons were rare codons for *E. coli* (Fig. 2). The N-terminal of the capsid protein is especially rich in arginine, where there are 22 arginines among the top 40 amino acids, accounting for 55%.

The results of the antigenic epitopes predicted by the online program Bepipred Linear Epitope Prediction 2.0 and ElliPro found that no linear epitopes or discontinuous B cell epitopes were detected in the first 33 amino acids of the coat protein, which indicates that the N

terminal 33 amino acids can be deleted without affecting antigenicity of the protein (Fig. 3). So, to determine the influence of high repetitive arginine in the expression of the *E. coli*, the intact PCV3 Cap (CAP) and a truncated Cap without anterior 32 amino acids (Δ CAP) were selected to express. At the same time, the codon-optimized Cap gene sequence was submitted into the GeneBank as Gene Accession Number MT452640. The codon-optimized Δ CAP gene sequence came from the codon-optimized Cap gene. They all were expressed to determine the influence of rare codon and dense arginine by comparison with that of the innate CAP and Δ CAP gene.

a				
No.	Start	End	Peptide	Length
1	39	64	YTKKYSTMNVISVGT PQNNKP WHANH	26
2	67	68	TR	2
3	71	71	E	1
4	97	143	AQQT KTM FGHTAIDLDGAWTNTWLQDDPYAESSTRK VMTSKKKH SR	47
5	155	161	TS AHPGQ	7
6	175	182	TYDPT VQW	8
7	190	210	YVPEKTGM TD FDYGT KEV WIRY	21
b				
No.	Start	End	Peptide	Length
1	149	154	PILAGT	6
2	70	83	NEWETAISFEYYKI	14
3	91	103	SPVISPAQ QTKTM	13
4	34	44	TAGTY YTKKYS	11
5	50	59	SV GTPQNNKP	10
6	127	131	AESST	5
c				
No.	Residues	Length	Score	
1	<u>._T34, _A35, _G36, _T37, _Y39, _E73, _T74, _A75, _I76, _S77, _F78</u>	11	0.885	
2	<u>._P149, _I150, _L151, _A152, _G153, _T154</u>	6	0.795	
3	<u>._S91, _P92, _V93, _I94, _S95, _P96, _A97, _Q98, _Q99, _T100, _K101, _T102, _M103, _S137, _K138, _K139</u>	16	0.649	
4	<u>._Y38, _T40, _K41, _K42</u>	4	0.603	
5	<u>._S50, _V51, _G52, _T53, _P54, _Q55, _N56, _N57, _K58, _P59, _T116, _T117, _N118, _T119, _W120, _L121, _Q122, _D123, _D124, _A127, _E128, _S129, _S130, _T131</u>	24	0.601	
6	<u>._R68, _N70, _E71, _W72</u>	4	0.5	

Fig. 2 Codon analysis of PCV3 capsid protein. The original gene of CAP protein has 23% rare codon (51/214) analyzed by online *E. coli* Codon Usage Analysis 2.0, which were replaced in the codon-optimized sequence without changing the amino acid sequence. The codon in the shadow represents a rare codon. The underlined sequence was removed in the truncated CAP protein (Δ CAP). The concentrated arginines area is in the box



Expression of recombinant capsid protein

The construct recombinant bacteria containing the pET-28a, pET-3CAP-O, pET-Δ3CAP-O, pET-3CAP, and pET-Δ3CAP vector were cultured in 5 mL ZYP-5052 medium for 24 h for expression of capsid protein. Then 1 g expressed cells harvested were used for the SDS-PAGE. The results showed that two obvious 25 kD protein bands appeared in the lands of recombinant bacteria pET-Δ3CAP-O and pET-Δ3CAP, respectively, whereas the lands of negative bacteria and recombinant bacteria pET-28a, pET-3CAP-O and pET-3CAP had no corresponding bands (Fig. 1a). It indicated that the codon optimization of CAP did not increase its expression in *E. coli*, but the truncation did. The grey value analysis of bands in the photo of SDS-PAGE showed that the recombinant ΔCAP in the bacteria containing pET-Δ3CAP-O and pET-Δ3CAP were constituted 6.2% and 6.1% of the total bacteria proteins, respectively (Table 2). It showed that the optimization of codon usage increased the expression of capsid protein to a negligible extent. On the other hand, it further reflects the extent to which the truncated processing improves the expression. In the western-blot, the proteins in both bands of ΔCAP were recognized by the antibody against 6 His-tag, respectively, but no band

Table 2 The grey value of expressed ΔCAP band and total bacteria analyzed by the ImageJ software

	Bacteria with plasmid pET-Δ3CAP	Bacteria with plasmid pET-Δ3CAP-O
Expressed ΔCAP	8067.335	5409.92
Total	132229.8	87124.77
Percent of expressed ΔCAP	6.1%	6.2%

appears in both lanes of recombinant CAP (Fig. 1b). It further showed that the optimization of codon did not affect the expression.

Purification of the recombinant ΔCAP protein


The recombinant ΔCAP from *E. coli* with the pET-Δ3CAP-O plasmid was purified using Ni-NTA column according to the manufacturer's instruction. SDS-PAGE gels identified three fractions. The ΔCAP with a purity of 95% mainly appeared in the elution with 100 mM imidazole and migrated as one defined band with 26 kDa (Fig. 4a). Western-Blot assay with positive serum of PCV3 and goat anti-pig IgG (Sangon Biotech Co., Ltd., Shanghai, China) showed that the positive serum of pig also recognized the proteins in the bands with PCV3 infection (Fig. 4b). It manifested that the recombinant protein is the capsid protein of PCV3, and it has immunoactivity.

Transmission electron microscopy (TEM)

The purified ΔCAP in the elution with 100 mM imidazole was observed under transmission electron microscopy (TEM). There existed numerous particles with similar morphology of circovirus (Xiao et al. 2018) and the diameter ranging from 15 to 20 nm (mean 17 nm), which were the same homogenous in size and morphology as PCV2 virus particles (Fig. 5). So, the result showed that the ΔCAP purified from the *E. coli* cells was assembled into virus-like particles (VLP).

Discussion

In our present study, we investigated which factor of the rare codon or the dense arginine is a more important obstacle in the expression of PCV3 Cap protein. To






Fig. 5 Transmission electron micrographs of Δ CAP. Virus-like particles (VLPs) formed by purified Δ CAP proteins expressed in *E. coli* cells were viewed using an HT7700 operating at 120 kV

clarify it, innate, codon-optimized, truncated, truncated and codon-optimized CAP proteins were expressed in *E. coli*. Our results showed that the deletion of anterior high repetitive arginine could improve the expression of Cap protein in *E. coli* and didn't influence the formation of virus-like particles.

Rare codon analysis showed that the anterior N-terminal of PCV3 capsid protein contained a large number of rare codons, which were concentrated and repeated (Fig. 2). For the expression of a protein in the pET28a expression vector, the number of rare codons and their concentration degree are the important affecting factors (Karimi et al. 2015; Nouri et al. 2016). So the innate Cap protein almost wasn't expressed in *E. coli*, while the truncated Cap protein was obviously expressed.

Moreover, after optimizing the rare codon, the expression of the whole and truncated Cap still showed a huge difference. Although the truncated CAP protein still contained a large number of rare codons, its expression was similar to the codon-optimized truncated cap protein. This demonstrated that highly repetitive arginine is a more obvious obstacle in the expression of PCV3 capsid protein in *E. coli* than rare codons. To the best of my knowledge, this is the first report of the effects of repeat codons in the expression of PCV3 Cap protein. Whether this effect also occurs on other amino acids in other proteins requires further study.

It is reported that PCV2 capsid protein without a nuclear localization signal (NLS) still forms virus-like particles (VLP), which were less homogenous in size and morphology than the typical circovirus (Zhou et al. 2005; Xiao et al. 2018). The VLP formation of purified PCV3

Δ CAP was also examined in this study. The VLPs of Δ CAP had typical circovirus morphology and size. The differences of VLP of truncated Cap protein of PCV2 and PCV3 may be due to viral proteins and truncated region.

PCV3 is being a new focus of attention in all pig-producing areas of the world, so developing a vaccine is a need. Because PCV3 has not been successfully cultured so far (Deng et al. 2018), the expression of antigen in vitro becomes the first choice for vaccine preparation. For a vaccine, capsid proteins must be expressed efficiently at low production costs. The prokaryotic expression system is the most appropriate. The results of this study are conducive to the high expression of PCV3 Cap protein for the preparation of subunit vaccines to prevent and control the PCV3 infection.

In conclusion, the study proved that the main obstructive factor of the expression of PCV3 CAP protein in *E. coli* was high repetitive arginines located in its anterior region. Rare codon has few influences on its expression in *E. coli*. The truncated capsid protein without the anterior concentrated arginines could be assembled into intact viral protein. It provides a preliminary reference for the production of the recombinant PCV3 capsid protein for the vaccine or other studies.

Acknowledgements

Not applicable.

Authors' contributions

LBS designed the study and drafted the manuscript. LBY, GB, LMZ, and ZTT performed experimental work. All authors contributed to the critical review and revision of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Education Department of Liaoning Province (LSNFW201710, LSNYB201612) and the National Key Program for Infectious Disease of China (2018ZX10732401-001, 2018ZX10101002-002). They played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

All data generated or analyzed during this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 11 May 2020 Accepted: 8 December 2020

Published online: 11 December 2020

References

Chae C (2012) Commercial porcine circovirus type 2 vaccines: efficacy and clinical application. *Vet J* 194:151–157

- Deng J, Li X, Zheng D, Wang Y, Chen L, Song H, Wang T, Huang Y, Pang W, Tian K (2018) Establishment and application of an indirect ELISA for porcine circovirus 3. *Arch Virol* 163:479–482
- Faccini S, Barbieri I, Gilioli A, Sala G, Gibelli LR, Moreno A, Sacchi C, Rosignoli C, Franzini G, Nigrelli A (2017) Detection and genetic characterization of Porcine circovirus type 3 in Italy. *Transbound Emerg Dis* 64:1661–1664
- Franzo G, Legnardi M, Hjulsgager CK, Klauermann F, Larsen LE, Segales J, Drigo M (2018) Full-genome sequencing of porcine circovirus 3 field strains from Denmark, Italy and Spain demonstrates a high within-Europe genetic heterogeneity. *Transbound Emerg Dis* 65:602–606
- Hayashi S, Ohshima Y, Furuya Y, Nagao A, Oroku K, Tsutsumi N, Sasakawa C, Sato T (2018) First detection of porcine circovirus type 3 in Japan. *J Vet Med Sci* 80:1468–1472
- Karimi Z, Nezafat N, Negahdaripour M, Berenjian A, Hemmati S, Ghasemi Y (2015) The effect of rare codons following the ATG start codon on expression of human granulocyte-colony stimulating factor in *Escherichia coli*. *Protein Expr Purif* 114:108–114
- Kwon T, Yoo SJ, Park CK, Lyoo YS (2017) Prevalence of novel porcine circovirus 3 in Korean pig populations. *Vet Microbiol* 207:178–180
- Li G, He W, Zhu H, Bi Y, Wang R, Xing G, Zhang C, Zhou J, Yuen KY, Gao GF, Su S (2018) Origin, genetic diversity, and evolutionary dynamics of novel porcine Circovirus 3. *Adv Sci (Weinh)* 5:1800275
- Nouri HR, Karkhah A, Varasteh A, Sankian M (2016) Expression of a chimeric allergen with high rare codons content in codon bias-adjusted *Escherichia coli*: *Escherichia coli* BL21 (DE3)-codon plus RIL as an efficient host. *Curr Microbiol* 73:91–98
- Palinski R, Piñeyro P, Shang P, Yuan F, Guo R, Fang Y, Byers E, Hause BM (2017) A Novel porcine circovirus distantly related to known circoviruses is associated with porcine dermatitis and nephropathy syndrome and reproductive failure. *J Virol* 91:e01879–e01816
- Stadejek T, Woźniak A, Miłek D, Biernacka K (2017) First detection of porcine circovirus type 3 on commercial pig farms in Poland. *Transbound Emerg Dis* 64:1350–1353
- Studier FW (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41:207–234
- Tochetto C, Lima DA, Loiko APMV, Paim MR, Scheffer WP, Herpich CM, Cerva JI, Schmitt C, Cibulski C, Santos SP, Mayer AC, Roehe FQ PM (2018) Full-Genome Sequence of Porcine Circovirus type 3 recovered from serum of sows with stillbirths in Brazil. *Transbound Emerg Dis* 65:5–9
- Xiao Y, Zhao P, Du J, Li X, Lu W, Hao X, Dong B, Yu Y, Wang L (2018) High-level expression and immunogenicity of porcine circovirus type 2b capsid protein without nuclear localization signal expressed in *Hansenula polymorpha*. *Biologicals* 51:18–24
- Ye X, Berg M, Fossum C, Wallgren P, Blomström AL (2018) Detection and genetic characterization of porcine circovirus 3 from pigs in Sweden. *Virus Genes* 54:466–469
- Yu C, Li X, Liu J, Diao W, Zhang L, Xiao Y, Wei H, Yu Y, Yu Y, Wang L (2016) Replacing the decoy epitope of PCV2b capsid protein with a protective epitope enhances efficacy of PCV2b vaccine. *Vaccine* 34:6358–6366
- Yuzhakov AG, Raev SA, Alekseev KP, Grebennikova TV, Verkhovskiy OA, Zaberezhny AD, Aliper TI (2018) First detection and full genome sequence of porcine circovirus type 3 in Russia. *Virus Genes* 54:608–611
- Zhai SL, Zhou X, Zhang H, Hause BM, Lin T, Liu R, Chen QL, Wei WK, Lv DH, Wen XH, Li F, Wang D (2017) Comparative epidemiology of porcine circovirus type 3 in pigs with different clinical presentations. *Virol J* 14:222
- Zhang H, Qian P, Peng B, Shi L, Chen H, Li X (2015) A novel subunit vaccine co-expressing GM-CSF and PCV2b Cap protein enhances protective immunity against porcine circovirus type 2 in piglets. *Vaccine* 33:2449–2456
- Zhang J, Liu Z, Zou Y, Zhang N, Wang D, Tu D, Yang L, Deng Z, Yang Y, Jiang P, Wang N (2018) First molecular detection of porcine circovirus type 3 in dogs in China. *Virus Genes* 54:140–144
- Zhou JY, Shang SB, Gong H, Chen QX, Wu JX, Shen HG, Chen TF, Guo JQ (2005) In vitro expression, monoclonal antibody and bioactivity for capsid protein of porcine circovirus type II without nuclear localization signal. *J Biotechnol* 118:201–211

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)